The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types

Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, Kufer P, Iskander K, Kantarjian HM (2020)

Publication Type: Journal article, Review article

Publication year: 2020

Journal

Cancer Wiley-Blackwell

Book Volume: 126

Pages Range: 3192-3201

Journal Issue: 14

DOI: 10.1002/cncr.32909

Abstract

Immuno-oncology therapies engage the immune system to treat cancer. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that connects patients' own T cells to malignant cells. The modular nature of BiTE technology facilitates the generation of molecules against tumor-specific antigens, allowing off-the-shelf immuno-oncotherapy. Blinatumomab was the first approved canonical BiTE molecule and targets CD19 surface antigens on B cells, making blinatumomab largely independent of genetic alterations or intracellular escape mechanisms. Additional BiTE molecules in development target other hematologic malignancies (eg, multiple myeloma, acute myeloid leukemia, and B-cell non-Hodgkin lymphoma) and solid tumors (eg, prostate cancer, glioblastoma, gastric cancer, and small-cell lung cancer). BiTE molecules with an extended half-life relative to the canonical BiTE molecules are also being developed. Advances in immuno-oncology made with BiTE technology could substantially improve the treatment of hematologic and solid tumors and offer enhanced activity in combination with other treatments.

Involved external institutions

Julius-Maximilians-Universität Würzburg DE Germany (DE) Fox Chase Cancer Center US United States (USA) (US) University of Texas MD Anderson Cancer Center US United States (USA) (US) Ludwig-Maximilians-Universität (LMU) DE Germany (DE) New York Presbyterian Hospital US United States (USA) (US) Amgen GmbH DE Germany (DE) Amgen Inc. US United States (USA) (US)

How to cite

APA:

Einsele, H., Borghaei, H., Orlowski, R.Z., Subklewe, M., Roboz, G.J., Zugmaier, G.,... Kantarjian, H.M. (2020). The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer, 126(14), 3192-3201. https://doi.org/10.1002/cncr.32909

MLA:

Einsele, Hermann, et al. "The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types." Cancer 126.14 (2020): 3192-3201.

BibTeX: Download